伊桂叶, 王家泰, 董萍, 周蒨, 李晗. 西格列汀治疗2型糖尿病肥胖患者40例疗效观察[J]. 蚌埠医学院学报, 2013, 37(4): 434-436.
    引用本文: 伊桂叶, 王家泰, 董萍, 周蒨, 李晗. 西格列汀治疗2型糖尿病肥胖患者40例疗效观察[J]. 蚌埠医学院学报, 2013, 37(4): 434-436.
    YI Gui-ye, WANG Jia-tai, DONG Ping, ZHOU Qian, LI Han. The clinical curative effect of sitagliptin in the treatment of obesity type 2 diabetes:a report of 40 cases[J]. Journal of Bengbu Medical College, 2013, 37(4): 434-436.
    Citation: YI Gui-ye, WANG Jia-tai, DONG Ping, ZHOU Qian, LI Han. The clinical curative effect of sitagliptin in the treatment of obesity type 2 diabetes:a report of 40 cases[J]. Journal of Bengbu Medical College, 2013, 37(4): 434-436.

    西格列汀治疗2型糖尿病肥胖患者40例疗效观察

    The clinical curative effect of sitagliptin in the treatment of obesity type 2 diabetes:a report of 40 cases

    • 摘要: 目的:探讨西格列汀对2型糖尿病肥胖患者(血糖控制)的临床疗效。方法:将40例血糖控制欠佳的肥胖2型糖尿病患者,在原治疗方案基础上加用西格列汀进行为期12周治疗。分别于治疗前及治疗12周后测定患者的空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖基化血红蛋白(HbA1c),C肽、餐后2 h C肽,血常规、血压、肝肾功能。结果:西格列汀治疗12周后FBG及2hPG、HbA1c、体质量指数和胰岛素剂量均较治疗前下降(P0.05~P0.01),C肽及餐后2 h C肽水平均较治疗前提高(P0.01)。治疗后血压、肝肾功能、血红细胞和血小板均无明显变化(P0.05),而血白细胞较治疗前降低(P0.01)。结论:西格列汀是治疗2型糖尿病肥胖患者有效且安全的口服降糖药。

       

      Abstract: Objective:To observe the clinical curative effects of sitagliptin in the treatment of obesity type 2 diabetes.Methods:Forty cases with type 2 diabetes without fine control of blood glucose level were treated with sitagliptin for 12 weeks,which was based on original clinical protocols.The levels of fasting blood glucose(FBG),2 hour postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c),c-peptide and 2 h c-peptide,and the blood routine,blood pressure and the liver and kidney functions were detected before treatment and at 12 weeks after treatment.Results:Compared with before treatment,the levels of FBG,2hPG,HbA1c,BMI and insulin dose decreased significantly(P0.05 to P0.01).The levels of c-peptide and 2 h c-peptide improved(P0.01) at 12 weeks after treatment with sitagliptin.There were no significant changes in the levels of blood pressure,and the liver and kidney functions,red blood cells and platelets after treatment(P0.05).The white blood cells after treatment were lower than those before treatment(P0.01).Conclusions:Sitagliptin is a safe and effective hypoglycemic drug in the treatment of obesity type 2 diabetes and without obvious adverse effects.

       

    /

    返回文章
    返回